Every medical device that enters the human body whether it touches the skin, contacts blood or is permanently implanted carries a biological risk. Before that device can be approved for clinical use, manufacturers must answer a fundamental question: Is this device safe for the patient?

Biocompatibility testing is the systematic scientific process used to answer that question. It evaluates whether a device’s materials, coatings, and chemical constituents cause harm when they interact with living tissue. Far from being a checkbox exercise, biocompatibility is the cornerstone of both patient protection and market access and getting it right from the start can mean the difference between a smooth regulatory approval and a costly product recall.

What Is Biocompatibility Testing?

Biocompatibility is defined as the ability of a material to perform its intended function without eliciting a harmful local or systemic response in the patient. The gold standard framework for evaluating biocompatibility is the ISO 10993 series — a set of internationally recognized standards developed specifically for medical devices.

ISO 10993-1 serves as the overarching standard and establishes a risk-based approach to biological evaluation. Rather than mandating blanket testing for every device, it requires manufacturers to conduct a structured biological evaluation that considers:

•         The nature of patient contact (skin, mucosa, blood, implant)

•         The duration and frequency of contact (limited, prolonged, permanent)

•         The materials and their known chemical constituents

•         Historical clinical data and equivalent material comparisons

•         The potential for leachables and extractables to migrate into the body

This risk-based philosophy means that biocompatibility evaluation is not just about running tests — it is a thoughtful scientific exercise that draws on chemistry, toxicology, material science, and regulatory knowledge.

The Patient Safety Imperative

When biocompatibility is overlooked or inadequately addressed, the consequences for patients can be severe. The human body’s response to foreign materials ranges from mild irritation to life-threatening systemic toxicity. Common biological hazards associated with poorly evaluated devices include:

•         Cytotoxicity: Cell death caused by toxic leachables, which can delay healing and damage surrounding tissue.

•         Sensitization: Allergic responses triggered by chemical residues, potentially causing severe reactions upon re-exposure.

•         Genotoxicity: DNA damage from chemical constituents that may increase cancer risk over time.

•         Hemocompatibility issues: Blood clotting, hemolysis, or thrombosis in devices that contact the cardiovascular system.

•         Chronic inflammation: Persistent inflammatory responses around implanted devices that can lead to fibrosis or implant failure.

These risks are not theoretical. History is filled with examples of devices that reached patients before adequate biocompatibility evaluation was completed, resulting in harm, litigation, and costly market withdrawals. Rigorous, early-stage biocompatibility assessment is the most effective tool manufacturers have to prevent these outcomes.

The Regulatory Landscape: ISO 10993, FDA, and EU MDR

Regulatory bodies around the world require documented biological safety evidence before granting device approval. Understanding what each authority expects is essential to building a compliant submission.

FDA Requirements

The U.S. Food and Drug Administration (FDA) recommends manufacturers to follow FDA Guidance Document for ISO 10993-1 as the foundation of their biocompatibility strategy. For 510(k) submissions, PMA applications, and De Novo requests, FDA reviewers scrutinize the Biological Evaluation Report (BER) closely. A poorly constructed BER or one that relies solely on testing without appropriate toxicological risk assessment is a leading cause of additional information requests and submission delays.

EU MDR Requirements

The European Medical Device Regulation (EU MDR 2017/745) has raised the bar significantly for biological safety documentation compared to its predecessor, the MDD. Manufacturers must now provide a comprehensive biological evaluation as part of the Technical Documentation, with explicit Tolerable Intake (TI) values, toxicological risk assessments per ISO 10993-17, and chemical characterization per ISO 10993-18. Notified Bodies are reviewing these sections with increasing scrutiny, and incomplete documentation is a common cause of certification delays.

Global Harmonization

ISO 10993 is recognized or adopted as the standard for biocompatibility evaluation in most major markets including Canada (Health Canada), Japan (PMDA), Australia (TGA), and Brazil (ANVISA). Building a robust, ISO 10993-aligned biological evaluation not only satisfies FDA and EU MDR requirements but also creates a foundation that can be adapted for global submissions with minimal additional effort.

Key Components of a Biocompatibility Evaluation

A complete biological evaluation under ISO 10993-1 is not a single test — it is a structured assessment that may include some or all of the following components, depending on the device’s risk profile:

•         Biological Evaluation Plan (BEP): A documented strategy that defines the scope of the evaluation, the endpoints to be assessed, the justification for testing or waiving tests, and the acceptance criteria.

•         Material Characterization: Identification of all materials in patient contact and review of existing safety data, supplier specifications, and historical use.

•         Chemical Characterization (ISO 10993-18): Extractables and leachables (E&L) studies to quantify what chemicals may migrate from the device into the body.

•         Toxicological Risk Assessment (ISO 10993-17): Calculation of patient exposure doses and comparison against established toxicological thresholds (e.g., TDI, ADE, TTC).

•         Biological Testing: Laboratory tests such as cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, hemocompatibility, and implantation, where indicated.

•         Biological Evaluation Report (BER): The final integrated document summarizing all findings, risk conclusions, and residual risk management decisions.

How Early Testing Accelerates Market Approval

One of the most common and costly mistakes in medical device development is treating biocompatibility as an afterthought. When biological evaluation is initiated late in the development cycle, it creates several downstream risks:

•         Material changes required after testing can trigger re-verification and re-validation, adding months and significant cost.

•         Late-stage test failures may require redesign when it is most expensive to do so.

•         Incomplete documentation at submission leads to Requests for Additional Information (RAI) from FDA or queries from Notified Bodies, each of which can add 3-6 months to approval timelines.

•         Failure to align the biological evaluation strategy with the intended regulatory pathway can result in a fundamentally flawed submission.

By contrast, integrating biocompatibility strategy at the material selection phase before any tooling or manufacturing commitments are made, allows teams to select materials with well-established safety profiles, build a defensible risk-based rationale for testing decisions, and produce high-quality documentation that stands up to regulatory scrutiny on first review.

The Role of Toxicological Risk Assessment

A significant evolution in the ISO 10993 framework over the past decade has been the growing emphasis on toxicological risk assessment (TRA) as an alternative or complement to biological testing. Rather than automatically defaulting to in vivo animal studies, ISO 10993-17 provides a framework for calculating patient exposure to chemical substances expressed as Tolerable Intake (TI) values and comparing this against established toxicological limits.

This approach has several important advantages. It reduces reliance on animal testing (aligning with the 3Rs principles of Replace, Reduce, and Refine). It provides a more mechanistic, scientifically defensible assessment than binary pass/fail test results. And it allows manufacturers to justify the waiver of certain biological tests when the chemical evidence demonstrates negligible patient risk.

Both FDA and EU MDR now expect robust TRA as part of the biological evaluation package, particularly for implantable and long-term contact devices.

Common Pitfalls and How to Avoid Them

After working with medical device companies across FDA, EU MDR, and global markets, we have identified recurring patterns that derail biocompatibility evaluations:

•         Relying solely on material data sheets (MDS): Supplier MDS documents rarely provide sufficient toxicological depth for a regulatory submission. A proper material and chemical characterization (if needed) and TRA is required.

•         Assuming ISO 10993 compliance equals regulatory acceptance: ISO 10993 is the framework, but FDA and EU MDR have specific interpretation guidance that must also be followed.

•         Neglecting finished device testing: Testing individual materials is not the same as testing the finished, processed device. Sterilization, packaging and manufacturing processes can introduce new chemical residues.

•         Inadequate documentation: The BER must tell a complete scientific story. Regulators expect transparent methodology, justified decisions, and clear risk conclusions.

•         Waiting until product launch to address legacy compliance: Changes in regulation (particularly EU MDR) require that even legacy products undergo updated biological evaluations.

Conclusion: Safety First, Approval Follows

Biocompatibility testing is not a regulatory hurdle to be cleared as quickly as possible. It is the scientific foundation upon which patient trust in your device is built. When approached rigorously and strategically — with a well-constructed Biological Evaluation Plan, thorough chemical characterization, expert toxicological risk assessment, and targeted laboratory testing it protects patients, accelerates regulatory approval, and reduces the risk of costly post-market surprises.

At Eunoia Compliance, we partner with medical device manufacturers at every stage of the biological evaluation process from early material selection and gap analysis through testing strategy, TRA, and final BER compilation. Our goal is simple: to help you bring safe devices to market, faster.

Dr. Priyanka Murawala is the founder of Eunoia Compliance, a specialized consultancy focused on biological safety and regulatory compliance for medical devices. With over 10 years of experience in biocompatibility, toxicological risk assessment, and ISO 10993 strategy, she has supported more than 50 product approvals across FDA, EU MDR, and global markets. She is based in Bar Harbor, ME, USA.